What's new

[PIO] COVID-19: Recommendations for the use of customized vaccines

29969.jpg




The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) have issued a joint statement providing updated public health considerations on the use of the newly approved adapted COVID-19 vaccines to support the planning of autumn and winter vaccination campaigns.

The EU recently expanded its arsenal with two new updated vaccines, Comirnaty Original/Omicron BA.1 and Spikevax Bivalent Original/Omicron BA.1. As the SARS-CoV-2 virus continues to grow, existing vaccines are being adapted to ensure optimal protection of EU citizens against COVID-19.

The two bivalent formulations for use as booster doses, recently proposed by the EMA for approval, extend immunity against variants of concern, especially Omicron and related sub-variants. Exposing the immune system to modern versions of the virus, so that it recognises subsequent variants, is key to creating a broader immune response.

Recommended use of the tailored booster vaccines

Although these first two tailored vaccines have been licensed for use in people aged 12 years and older who have received at least the initial COVID-19 vaccination regimen, the ECDC and EMA advise that these booster doses should be targeted primarily to people who are at higher risk of severe disease due to specific risk factors. These include people aged 60 years and older, immunocompromised and other vulnerable individuals (12 years and older) with underlying conditions that put them at higher risk of severe COVID-19 disease and pregnant women. In addition, residents and staff of long-term care facilities should be given priority. Healthcare workers may also be considered due to their increased exposure in case of future new waves of SARS-CoV-2 and their key role in the proper functioning of healthcare systems.

"The licensing of the first two adapted vaccines is an important step in our ongoing fight against the pandemic," said EMA Executive Director Emer Cooke.

"We have a virus that evolves rapidly and unpredictably. It is important for the EU to have a wide range of vaccines that are up-to-date in terms of their formulation so that Member States have more options to meet their needs when planning their vaccination strategies."

He added that "Health authorities in the EU have done everything they could to get people vaccinated."

ECDC Director Dr. Andrea Ammon, stressed the importance of vaccines in the fight against the COVID-19 pandemic.

"With the newly licensed adapted COVID-19 vaccines, Member States will now have a wider range of options to launch autumn/winter vaccination campaigns against COVID-19 to protect the most vulnerable groups and boost their immunity against the most recent variants," said Dr. Ammon.

"As the newer vaccines are at this stage licensed for use only as booster doses, prototype vaccines remain necessary to increase vaccination coverage with an initial vaccination regimen in the unvaccinated population to close immunization gaps."

Autumn vaccination programme

Timely vaccination and booster doses in view of a possible autumn and winter outbreak of COVID-19 cases is essential to protect people and prevent overloading of health systems. People in vulnerable groups who have not yet been vaccinated against COVID-19 or who have not received a booster dose are advised to come forward for vaccination as recommended in their countries.

The recently licensed adapted vaccines are only approved for use as booster doses in people who have completed at least the initial vaccination regimen, regardless of which vaccines were used in that regimen.

The original COVID-19 vaccines continue to provide protection against serious disease, hospitalisation and death and should be used for the initial vaccination regimen and considered for use as booster doses when newer adapted vaccines are not yet available.

Future adapted vaccines

Further adjustments to the formulation of COVID-19 vaccines are unavoidable to address existing and future circulating variants. Preliminary data suggest that the immune response induced by the approved adapted BA.1 vaccines extends beyond the selected strains and covers other Omicron sub-variants such as BA.2, BA.2.75 and BA.5.

In addition to the two licensed custom vaccines targeting the Omicron BA.1 sub-variant and the original SARS-CoV-2 strain, EMA is evaluating a custom vaccine that matches the original strain and the Omicron BA.4 and BA.5 sub-variant. There are also evaluations underway for vaccines including the beta strain of the virus. If licensed, these vaccines would further expand the options for vaccination.

Factors to consider in vaccination campaigns

National authorities in the EU make the final decisions on the availability of vaccines, including booster doses and type of vaccines, taking into account factors such as the spread of infection, the impact of COVID-19 in different populations and the emergence of new variants. These parameters will determine which vaccines to receive and when, based on the risk level of individuals and the epidemiological situation.

The ECDC and EMA will continue to closely evaluate the efficacy of emerging vaccines and epidemiological data and will update their recommendations accordingly.

(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO

Source

 
Back
Top